source
- Ultragenyx cuts 20% of workforce and abandons Wilson disease gene therapy after mixed Q3 resultsUltragenyx said it will cut about 20% of its workforce, marking a second round of layoffs this year. The reductions will affect roughly a fifth of the company's employees. At the same time, the fi…
- Live discussion to assess how US midterm elections could reshape biopharma policyDrew Armstrong, executive editor of PharmaFDA+, announced a live webcast at 1:30 pm ET on November 3, 2026 to discuss the impact of the US midterm elections on biotech and pharma. The program will…